TDB-DST Supports Indo-Canada R&D Project to Advance Continuous Health Monitoring Technology

The project, titled “Multivital Continuous Glucose Monitoring (CGM) Device with Cardiovascular Biomarkers for Early Detection of Heart Conditions alongside Diabetes Monitoring,” focuses on integrating advanced cardio-metabolic biomarkers into existing continuous glucose monitoring systems.

The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has agreed with M/s Drstore Healthcare Service India, a Maharashtra-based medical devices startup, to support the development of a next-generation health monitoring technology focused on continuous and preventive care.

The project has received grant assistance under the Indo-Canada Collaborative Industrial Research & Development Programme and aims to integrate continuous glucose monitoring with cardiovascular risk assessment.

The initiative has been taken up in collaboration with Canadian partner M/s Nanospeed Diagnostics under a bilateral framework involving DST, the National Research Council Canada, and Global Affairs Canada. The Indo-Canada programme is designed to encourage industry-led, market-oriented research that can translate into commercially viable solutions with societal relevance, particularly in critical sectors such as healthcare.

Sh. Rajesh Kumar Pathak, Secretary, TDB, stated that “technology-led preventive healthcare solutions are critical to reducing long-term disease burden. Projects supported under international collaborative frameworks such as the Indo-Canada Programme enable Indian industry to access global knowledge while building indigenous, scalable solutions for national health priorities.”

The supported project, titled “Multivital Continuous Glucose Monitoring (CGM) Device with Cardiovascular Biomarkers for Early Detection of Heart Conditions alongside Diabetes Monitoring,” focuses on integrating advanced cardio-metabolic biomarkers into existing continuous glucose monitoring systems.

These biomarkers include B-type Natriuretic Peptide (BNP), Troponin-I, and high-sensitivity C-Reactive Protein (hs-CRP), which are widely used indicators for assessing cardiac stress, myocardial injury, and inflammation.

By leveraging the CGM mechanism that analyses interstitial fluid, the proposed health monitoring technology aims to enable simultaneous, continuous tracking of glucose levels and early cardiovascular risk indicators. This approach addresses the growing burden of co-morbidities such as diabetes and heart disease, which often require frequent hospital visits and episodic diagnostic tests for effective management.

The project is expected to support home-based monitoring, early detection of cardiac conditions, and remote clinical oversight, reducing dependence on hospital-centric care models.

It also aligns with national priorities related to affordable healthcare access, digital health adoption, and the indigenous development of advanced medical devices tailored to Indian conditions.

M/s Drstore Healthcare Service India has been working in the area of preventive and remote healthcare monitoring solutions. With TDB support, the company plans to validate the technological feasibility of the integrated platform and establish a pathway for its commercial deployment as a multi-vital health monitoring technology.

Stay tuned for more such updates on Digital Health News